About centessa pharmaceuticals plc - CNTA
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
CNTA At a Glance
Centessa Pharmaceuticals Plc
1 Ashley Road
Altrincham, Cambridgeshire WA14 2DT
| Phone | 44-7391-789784 | Revenue | 15.04M | |
| Industry | Pharmaceuticals: Major | Net Income | -197,993,606.74 | |
| Sector | Health Technology | Employees | 118 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CNTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 225.756 |
| Price to Book Ratio | 7.084 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.527 |
| Enterprise Value to Sales | 214.036 |
| Total Debt to Enterprise Value | 0.037 |
CNTA Efficiency
| Revenue/Employee | 127,415.704 |
| Income Per Employee | -1,677,911.922 |
| Receivables Turnover | 0.249 |
| Total Asset Turnover | 0.024 |
CNTA Liquidity
| Current Ratio | 8.568 |
| Quick Ratio | 8.568 |
| Cash Ratio | 6.861 |
CNTA Profitability
| Gross Margin | 93.86 |
| Operating Margin | -1,384.613 |
| Pretax Margin | -1,304.753 |
| Net Margin | -1,316.88 |
| Return on Assets | -31.188 |
| Return on Equity | -42.652 |
| Return on Total Capital | -30.685 |
| Return on Invested Capital | -34.04 |
CNTA Capital Structure
| Total Debt to Total Equity | 22.469 |
| Total Debt to Total Capital | 18.347 |
| Total Debt to Total Assets | 17.152 |
| Long-Term Debt to Equity | 22.334 |
| Long-Term Debt to Total Capital | 18.236 |